West Pharmaceutical Services, Inc. reaffirmed earnings guidance for the full year 2024. For the period, the company expects net sales in a range of $3.000 billion to $3.025 billion. Organic net sales growth is expected to be approximately 2% to 3%.

Net sales guidance includes an estimated full-year 2024 headwind of $8 million based on current foreign currency exchange rates. Reported-diluted EPS (U.S. GAAP) expected to be in the range of $7.59 to $7.84.